RecruitingPhase 1Phase 2NCT07174583

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer

Sponsor

IDEAYA Biosciences

Enrollment

262 participants

Start Date

Oct 14, 2025

Study Type

INTERVENTIONAL

Conditions

Small Cell Lung Cancer Neuroendocrine Carcinomas Solid Tumor Show to Express DLL3

Summary

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment called IDE849 for people with certain types of cancer that carry a protein called DLL3 — including small cell lung cancer and other neuroendocrine tumors. **You may be eligible if...** - You have been diagnosed with extensive-stage small cell lung cancer (SCLC), neuroendocrine carcinoma, or another tumor confirmed to express DLL3 - Your cancer has come back or gotten worse after standard treatment (such as platinum-based chemotherapy and immunotherapy) - You are willing and able to follow the study procedures and sign a consent form **You may NOT be eligible if...** - Your cancer has not been previously treated with standard therapies - You have certain other health conditions that the study team determines make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIDE849

IV administration

DRUGdurvalumab

IV administration

DRUGIDE161

oral administration

DRUGCarboplatin

IV administration

Locations(13)

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, United States

Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office

Fort Wayne, Indiana, United States

START Midwest

Grand Rapids, Michigan, United States

The Cancer and Hematology Centers

Grand Rapids, Michigan, United States

Columbia University Medical Center - Herbert Irving Pavilion

New York, New York, United States

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Sarah Cannon Research Institute - Oncology Partners

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Oncology Consultants, PA- Houston

Houston, Texas, United States

Next Oncology Dallas

Irving, Texas, United States

NEXT Oncology Virginia

Fairfax, Virginia, United States

Swedish Cancer Institute

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07174583

Related Trials

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT021461701 location

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

NCT069316263 locations

DESTINY-PANTUMOUR04

NCT0712400018 locations

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT0715517460 locations

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

NCT0725314210 locations